Miller T P, Cowan J D, Neilan B A, Jones S E
Cancer Chemother Pharmacol. 1986;16(1):67-9. doi: 10.1007/BF00255289.
Forty evaluable patients with malignant lymphoma (ML) were treated with bisantrene at a dose of 260 mg/m2 every 3 weeks (18 patients) or 208 mg/m2 every 3 weeks (22 patients). The initial dose rate was determined on the basis of expected myelosuppression. Patients were heavily pretreated and had advanced disease (92% had stage IV). The overall response rate was 10% and included 1 partial response (PR) in 17 patients with Hodgkin's disease (HD), 1 PR and 1 complete response (CR) in 5 patients with favorable histology in non-Hodgkin's lymphoma (NHL), and 1 PR in 18 patients with unfavorable histology in NHL. Neutropenia (WBC less than or equal to 3000 cells/microliter) was the most common toxicity, occurring in 50% of patients. Phlebitis was a common side effect in patients treated with bisantrene administered by way of peripheral veins. Bisantrene has limited activity in heavily pretreated patients with HD or unfavorable histology in NHL. The role of bisantrene for treatment of NHL with favorable histology or for treatment at an earlier point in the natural history of ML is unknown.
40例可评估的恶性淋巴瘤（ML）患者接受了比生群治疗，其中18例患者每3周接受260mg/m²的剂量，22例患者每3周接受208mg/m²的剂量。初始剂量率根据预期的骨髓抑制情况确定。患者均经过大量前期治疗且病情已进展（92%为IV期）。总体缓解率为10%，包括17例霍奇金淋巴瘤（HD）患者中有1例部分缓解（PR），5例组织学类型良好的非霍奇金淋巴瘤（NHL）患者中有1例PR和1例完全缓解（CR），18例组织学类型不良的NHL患者中有1例PR。中性粒细胞减少（白细胞计数小于或等于3000个/微升）是最常见的毒性反应，50%的患者出现该反应。静脉炎是通过外周静脉给予比生群治疗的患者中常见的副作用。比生群在经过大量前期治疗的HD患者或组织学类型不良的NHL患者中活性有限。比生群在组织学类型良好的NHL治疗中或在ML自然病程的早期治疗中的作用尚不清楚。
